- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NRAS Mutations in Melanoma
Richard W. Joseph, MD, highlights clinical trial results showing that melanoma patients with NRAS mutations tend to have better response rates to immunotherapy compared with patients with wild-type NRAS. NRAS mutations may be valuable predictors of response in patients with melanoma, suggests Dr Joseph.
Dr Joseph discusses previous research that investigated whether response rates for patients treated with high-dose interleukin-2 varied based on whether the patient had an NRAS mutation, a BRAF mutation, or were wild-type for both NRAS and BRAF. The results showed that patients with NRAS mutations responded better to treatment than patients with BRAF mutations or patients who were wild-type for both NRAS and BRAF. More recent research has demonstrated that patients with NRAS mutations also respond better when treated with other types of immunotherapies, he adds.
Although these results are exciting, there is still no definitive answer as to why melanoma patients with NRAS mutations respond better than patients without such mutations, remarks Dr Joseph. He is hopeful that additional studies will provide additional insight into the role of NRAS mutations in melanoma.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
